Results 91 to 100 of about 3,368,671 (295)
Molecular Oncology, EarlyView.Combining osimertinib with the STING agonist ADU‐S100 activates innate and adaptive immunity to overcome the non‐inflamed microenvironment of Egfr‐mutant lung cancer. This combination increases NK and CD8+ T‐cell infiltration, associated with activation of the STING‐IRF3 pathway and local immunogenic cell death.
Jun Nishimura +19 more
wiley +1 more source
Chapter: 11 Early Experiences at MD Anderson
, 2013 Dr. Bodey begins the chapter by noting the importance of the work done by Dr. Emil Frei and Dr. J Freireich at MD Anderson. He then observes that, prior to his own arrival at MD Anderson, no one had done large-scale studies of infectious diseases.
Bodey, Gerald P., MD +1 more
core
Eugenie Kleinerman, MD, Oral History Interview, June 18, 2014 [PDF]
, 2014 Major Topics Covered: Women in medicine and at MD Anderson Views on change at MD Anderson with shifts in executive leadershiphttps://openworks.mdanderson.org/mchv_interviewsessions/1247/thumbnail ...
Kleinerman, Eugenie S., MD +1 more
core
MITF maintains genome stability in nonmelanocyte lineages
Molecular Oncology, EarlyView.MITF is essential for melanocyte survival and acts as an oncogene in 10%–20% of melanomas. We show that MITF depletion causes genome instability in nonmelanocytic cells, leading to LATS2‐mediated P53 activation, cell cycle arrest, and apoptosis. This study highlights the role of MITF as a genome maintenance factor beyond the melanocyte lineage. Created
Drifa H. Gudmundsdottir +13 more
wiley +1 more source
Oncogenic DMTF1β promotes cancer cell motility by regulating autophagy through ULK1 stabilization
Molecular Oncology, EarlyView.In the current study, we demonstrate that the oncogene DMTF1β regulates ULK1 stability by reducing its proteasomal degradation in cancer cells. This stabilization enables ULK1 to induce autophagy, which in turn facilitates cancer cell migration. Consequently, reduced DMTF1β levels lead to decreased autophagy and impaired cancer cell migration.
Jun Xu +13 more
wiley +1 more source
Chapter 01: MD Anderson Presidents: Continuity and Sustained Institutional Growth
, 2012 In this Chapter, Dr. Mendelsohn first talks about his predecessors, Drs. R. Lee Clark and Charles LeMaistre. He then discusses the challenges that confronted him when he took over presidency of MD Anderson and reflects on what long presidential tenures ...
Mendelsohn, John, MD +1 more
core
Loss of proton‐sensing TDAG8 increases tumor progression in mouse models of colon cancer
Molecular Oncology, EarlyView.Loss of the pH‐sensing receptor TDAG8 accelerates colorectal cancer progression in mice. Animals lacking TDAG8 expression had increased tumor growth, DNA damage, and recruitment of tumor‐associated immune cells, including macrophages, neutrophils, and monocytes.
Ermanno Malagola +11 more
wiley +1 more source
, 2004 Dr. Cox talks about his decision to come to MD Anderson, his position as Vice President for Patient Care and Physician-in-Chief, and why that “title was a great title and it was a bad job, for me.” He also discusses being glad to return to being a ...
Cox, James D., MD, Brunet, Lesley W.
core
Louise Connally Strong, MD, Oral History Interview, August 10, 2012 [PDF]
, 2012 Major Topics Covered: Personal and educational background Overview and history of oncology genetics in the sixties and seventies Working with Alfred Knudson Research: longitudinal studies of inherited genetics patterns of neuroblastoma, aniridia, and ...
Strong, Louise Connally, MD +1 more
core
Molecular Oncology, EarlyView.Drug resistance limits treatment success in a subset of lung cancers driven by ROS1 gene alterations. Using patient‐derived cells and computer simulations, we studied three key mutations and how they affect five targeted drugs. The mutations reduced drug effectiveness in different ways by altering protein structure and behavior.
Farhan Ul Haq +8 more
wiley +1 more source